Table 2.
Statistically significant lipids according to study groups. Average intensity value normalized (x1000) to each lipid is shown with standard deviation, p value, VIP score and AUC.
| Total (n = 53) | No OSA (n = 16) | OSA (n = 37) | p value | VIP | CI dif. 95% | AUC (CI 95%) | |
|---|---|---|---|---|---|---|---|
| DAG(45:8) | 1.5 ± 0.3 | 1.7 ± 0.5 | 1.4 ± 0.3 | 0.022 | 2.016 | [−0.14; 5.23] | 0.699 (0.875–0.523) |
| Cer(d18:1/24:4) | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.044 | 2.540 | [−5.63; 0.13] | 0.676 (0.836–0.515) |
| PA(35:2) | 1.3 ± 0.2 | 1.4 ± 0.2 | 1.3 ± 0.2 | 0.064 | 3.780 | [−0.05; 2.42] | 0.662 (0.828–0.497) |
| PE(36:5) | 2.3 ± 0.8 | 1.8 ± 0.7 | 2.5 ± 1.0 | 0.023 | 3.426 | [−11.69; −1.50] | 0.698 (0.850–0.545) |
| PE(35:1) | 2.4 ± 1.3 | 1.5 ± 0.9 | 2.2 ± 1.1 | 0.018 | 3.516 | [−12.92; −1.30] | 0.704 (0.856–0.553) |
| PE(38:6) | 2.2 ± 1.0 | 1.7 ± 1.1 | 2.6 ± 1.5 | 0.032 | 3.893 | [−16.44; −1.46] | 0.688 (0.842–0.535) |
| PE(38:5) | 2.6 ± 1.3 | 1.6 ± 1.3 | 2.7 ± 1.6 | 0.019 | 4.301 | [−18.93; −2.04] | 0.705 (0.858–0.552) |
| PE(37:3) | 2.0 ± 0.9 | 1.7 ± 0.9 | 2.5 ± 1.3 | 0.018 | 3.768 | [−14.44; −1.74] | 0.704 (0.857–0.552) |
| PE(37:2) | 2.4 ± 1.2 | 1.9 ± 1.3 | 2.9 ± 1.7 | 0.024 | 4.180 | [−18.77; −1.78] | 0.696 (0.850–0.542) |
| PE(39:4) | 1.5 ± 0.6 | 1.2 ± 0.6 | 1.6 ± 0.07 | 0.040 | 2.749 | [−8.25; −0.67] | 0.679 (0.838–0.52) |
| PC(33:3) | 7.8 ± 2.4 | 8.8 ± 3.3 | 7.4 ± 2.9 | 0.030 | 3.761 | [−4.92; 34.14] | 0.694 (0.850–0.539) |
| PC(36:4) | 15.4 ± 2.3 | 16.4 ± 3.6 | 14.9 ± 3.4 | 0.021 | 3.548 | [−6.86; 36.31] | 0.706 (0.860–0.551) |
| PC(35:5) | 10.2 ± 1.6 | 10.9 ± 2.4 | 9.8 ± 2.3 | 0.019 | 2.974 | [−4.39; 24.70] | 0.709 (0.865–0.554) |
| PC(34:0) | 8.4 ± 2.1 | 9.3 ± 2.9 | 8.0 ± 2.6 | 0.022 | 3.505 | [−4.41; 30.31] | 0.704 (0.856–0.551) |
| PC(37:7) | 8.1 ± 1.3 | 8.5 ± 1.9 | 7.9 ± 1.9 | 0.074 | 2.055 | [−5.24; 17.79] | 0.661 (0.817–0.505) |
| PC(37:6) | 10.1 ± 1.6 | 10.8 ± 2.4 | 9.8 ± 2.3 | 0.030 | 2.883 | [−4.86; 24.70] | 0.694 (0.852–0.537) |
| PC(36:1) | 9.4 ± 1.6 | 10.0 ± 2.0 | 9.1 ± 2.2 | 0.037 | 2.730 | [−3.62; 21.58] | 0.687 (0.833–0.541) |
| SM(d18:1/12:0) | 2.8 ± 0.7 | 2.4 ± 1.0 | 3.0 ± 0.8 | 0.025 | 2.449 | [−12.35; −1.06] | 0.694 (0.860–0.529) |
| SM(d18:1/24:0) | 2.9 ± 0.5 | 2.5 ± 0.9 | 3.1 ± 0.5 | 0.038 | 2.304 | [−10.78; −0.46] | 0.681 (0.855–0.507) |
| SM(d18:1/26:1(17Z)) | 3.1 ± 0.4 | 2.8 ± 1.0 | 3.3 ± 0.4 | 0.048 | 2.157 | [−10.50; 0.16] | 0.666 (0.840–0.491) |
| LPC(27:1) | 2.1 ± 0.4 | 1.8 ± 0.5 | 2.2 ± 0.5 | 0.008 | 2.955 | [−7.41; −1.27] | 0.730 (0.882–0.578) |
| LPC(27:0) | 2.7 ± 0.8 | 2.4 ± 0.9 | 2.9 ± 0.9 | 0.01 | 2.837 | [−10.90; −0.10] | 0.671 (0.828–0.513) |
AUC: area under the curve; CI: confidence interval; DAG: diacylglycerol; Cer: ceramide; LPC: monoacylglycerophosphocholines (lyso-phosphocholines); PA: glycerophosphates; PC: glycerophosphocholines; PE: glycerophosphoethanolamines; OSA: obstructive sleep apnoea; SM: sphingomyelin; VIP: variable’s importance in the PLS-DA model.